CD19 and acute lymphoblastic leukemia: Since TRAIL/death receptor system plays an essential role in the anti-leukemic activities of immunotherapy using anti-CD19 CAR T-cells, our findings provide an epigenetic rationale for clinical efficacy of immunotherapy in BCP-ALL patients.